A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer
A Multicenter, Randomized, Controlled Phase Ⅲ Clinical Study on the Efficacy and Safety of Glumetinib in Combination With Osimertinib as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With Classic EGFR Mutations and MET Overexpression or Amplification
To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Clinical Trials Information Group officer
- Telefonnummer: 031169085587
- E-post: ctr-contact@cspc.cn
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Able to understand and willingness to voluntarily provide written informed consent.
- Age 18 to 75 years, males or females.
- Patientsconfirmed unresectable locally advanced or metastatic NSCLC patients;.
- Ability to provide qualified tumor samples..
- Patients must harbor the 1 of the 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., 19Del and L858R) as well as MET overexpression and/or amplification. MET overexpression and amplification must be confirmed by the central laboratory.
- No prior systemic anticancer therapy (including chemotherapy, radiotherapy, biological therapy, immunotherapy, or any investigational drugs) for locally advanced or metastatic NSCLC, and the participant is not amenable to curative surgery or radiotherapy. For patients with recurrent disease following prior surgery, if prior adjuvant chemo/radiotherapy, neoadjuvant chemo/radiotherapy, or definitive chemoradiotherapy for advanced disease was received, disease progression should have occurred ≥ 6 months after the completion of the last treatment.
- Presence of at least one measurable lesion at baseline according to RECIST v1.1. The target lesion must not have received prior irradiation, or if previously irradiated, must show documented evidence of disease progression after radiotherapy. Brain metastases cannot be selected as target lesions.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- Life expectancy ≥ 3 months.
- Adequate bone marrow reserve or organ function..
- Women of childbearing potential must use highly effective contraception. Women of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Any male or female participant of childbearing potential must agree to use highly effective contraception throughout the study period and for 6 months after the last dose.
Exclusion Criteria:
- Prior treatment with any EGFR inhibitor or MET inhibitor.
- Concomitant driver alterations such as ALK, ROS1, RAS, BRAF, RET, and HER2 for which approved targeted therapies are clinically available, if the Investigator judges that the patients cannot benefit from this trial due to the concomitant alteration; or other alterations (e.g., those with substantial clinical evidence supporting a better intervention for the mutation) that, in the Investigator's judgment, preclude benefit from this trial..
- Prior antineoplastic therapy within 2 weeks prior to the first dose of study drug, including hormonal therapy, biologic therapy, immunotherapy (including but not limited to anti-PD-1/PD-L1 antibodies, anti-CTLA-4 antibodies, cellular immunotherapy, etc.), local infusion of antineoplastic agents, or Chinese herbal medicines and/or proprietary Chinese patent medicines with approved/intended indications for the treatment of lung cancer.
- Prior local radiotherapy (including radionuclide therapy such as strontium-89) within 2 weeks before the first dose of study drug; or, within 4 weeks before randomization, received bone marrow irradiation exceeding 30% or extensive-field radiotherapy..
- Clinically uncontrolled (requiring paracentesis or drainage) malignant pleural effusion, ascites, or pericardial effusion within 2 weeks prior to the first dose of study drug.
- Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during the study period. Minor clinical procedures such as vascular access placement and core/needle biopsies are permitted.
- Presence of leptomeningeal carcinomatosis; presence of spinal cord compression; or symptomatic and unstable brain metastases, unless the participant has completed definitive treatment, has achieved neurological stability for at least 2 weeks prior to randomization, and requires no corticosteroids or anticonvulsants. Asymptomatic patients with brain metastases (e.g., without neurological deficits, seizures, or other typical signs/symptoms of central nervous system [CNS] metastasis) may be enrolled if the investigator assesses that there is no indication for immediate definitive intervention.
- Use of strong CYP3A4 inducers within 2 weeks prior to the first dose of study drug, or inability to discontinue strong CYP3A4 inducers during the study period.
- History of autoimmune diseases, immunodeficiency disorders (including positive HIV serology), other acquired or congenital immunodeficiency diseases, or history of solid organ or bone marrow transplantation.
- Active infection (e.g., the participant is receiving anti-infective therapy).
- Severe or uncontrolled cardiovascular diseases requiring medical treatment.
- History of hypersensitivity to the active or inactive excipients of osimertinib, gumarontinib/placebo, or chemotherapy agents (pemetrexed and cisplatin/carboplatin), or to drugs of similar chemical structure or class; contraindications to chemotherapy agents (pemetrexed and cisplatin/carboplatin).
- Failure to adequately recover from toxicities and/or complications resulting from any prior interventions prior to treatment initiation (i.e., not recovered to Grade ≤ 1, excluding fatigue or alopecia).
- Current diagnosis of other malignancies or a history of other active malignancies within 5 years prior to the first study treatment, with the exception of clinically cured localized neoplasms (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or papillary thyroid carcinoma).
- Definite prior history of neurological or psychiatric disorders, including epilepsy or dementia.
- Pregnant or lactating women.
- Participation in another investigational drug clinical trial and receipt of investigational drug within 3 weeks prior to the first dose of study drug.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A
Glumetinib 300 mg orally once daily (QD) + Osimertinib 80 mg orally QD,every 3 weeks |
Glumetinib 300 mg QD orally under fasting conditions Administered orally at a dose of 80 mg QD orally |
|
Placebo komparator: Arm B
Placebo 300 mg orally QD + Osimertinib 80 mg orallyQD,every 3 weeks |
Administered orally at a dose of 80 mg QD orally Placebo 300 mg QD orally under fasting conditions |
|
Aktiv komparator: Arm C
Osimertinib 80 mg QD and platinum-based chemotherapy Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. |
Administered orally at a dose of 80 mg QD orally Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
FS as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) |
Up to approximately 42 months after the first patient is enrolled
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
ORR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Objective response rate (ORR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
DCR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Disease control rate (DCR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
DOR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Duration of Response (DOR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
TTR as assessed by IRC
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Time to Response (TTR) as assessed by IRC |
Up to approximately 42 months after the first patient is enrolled
|
|
PFS as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
PFS as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
ORR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
ORR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
DCR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
DCR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
DOR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
DOR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
TTR as assessed by Investigator
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
TTR as assessed by Investigator |
Up to approximately 42 months after the first patient is enrolled
|
|
OS
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Overall Survival (OS) |
Up to approximately 42 months after the first patient is enrolled
|
|
Safety
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), the other safety variables including physical examination, vital signs and laboratory examinations. |
Up to approximately 42 months after the first patient is enrolled
|
|
PK parameters
Tidsramme: Up to approximately 42 months after the first patient is enrolled
|
Plasma concentration of Glumetinib |
Up to approximately 42 months after the first patient is enrolled
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Karsinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Guanin
- Hypoksantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sure
- Aminosyrer
- Aminosyrer, dikarboksyl
- Platinumforbindelser
- Pemetrexed
- Karboplatin
- Cisplatin
- Osimertinib
- glumetinib
Andre studie-ID-numre
Andre studie-ID-numre
- SYH2065-007
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .